BI 1291583 is a drug designed to reduce inflammation in the lungs of people with bronchiectasis, the progressive lung disease that occurs in cystic fibrosis and other conditions. In CF, bronchiectasis is driven by a vicious cycle of mucus buildup, infection, and inflammation that damages the lungs over time.

BI 1291583 works by inhibiting cathepsin C (CatC), an enzyme that exists naturally in the body and plays a key role in inflammation. When CatC is inhibited, or prevented from doing its job, the inflammation pathway is disrupted. This could allow BI 1291583 to reduce inflammation in the lungs of people with CF, improve symptoms, and help prevent permanent lung damage.

Status

A Phase 3 study to test the safety and effectiveness of BI 1291583 is currently underway. The study is enrolling both people with CF and people without CF that have bronchiectasis.

Sponsor

This program is sponsored by Boehringer Ingelheim. It is being conducted within the Therapeutics Development Network (TDN).